Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care

EAU 2026

12 - 16 Mar 2026

This video is restricted to healthcare professionals.

Please login or register for free to confirm your details.

Published: 24 Mar 2026

Views: 1670

Rating:

Save

Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte

Interactive industry seminar from EAU 2026 in London, featuring:

Welcome and introductions - Prof Jonathan Aning
Meet my patients: assessing patient risk in NMIBC - Dr Francesco Soria
Disease recurrence after BCG: what comes next today? - Dr Alexandra Masson-Lecomte
Strategies for risk stratification and assessment of response to BCG: Today’s challenges and how to overcome them - All faculty, led by Prof Jonathan Aning
Final remarks and closing - Prof Jonathan Aning

Related Videos

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC ( Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan )

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC ( Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands )

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer ( Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA )

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland, USA

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer ( Prof Daniel Spratt - University Hospitals Cleveland Medical Center, Cleveland, USA )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

More from ecancer